Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Connie A. Haley, Patricia Macias, Supriya Jasuja, Betsy A. Jones, Marie‐Claire Rowlinson, Roshni Jaimon, Pennelyn Onderko, Elaine Darnall, et al. (12 authors)
Emerging infectious diseases · 2020-11
Abstract
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
MeSH terms
- Bedaquiline
- Linezolid
- Regimen
- Medicine
- Tuberculosis
- Drug
- Extensively drug-resistant tuberculosis
- Drug resistance
- Food and drug administration
- Internal medicine
- Pharmacology